These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30877090)

  • 1. Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study.
    Diabetes Prevention Program Research Group
    Diabetes Care; 2019 Apr; 42(4):601-608. PubMed ID: 30877090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.
    Aroda VR; Knowler WC; Crandall JP; Perreault L; Edelstein SL; Jeffries SL; Molitch ME; Pi-Sunyer X; Darwin C; Heckman-Stoddard BM; Temprosa M; Kahn SE; Nathan DM;
    Diabetologia; 2017 Sep; 60(9):1601-1611. PubMed ID: 28770322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
    Ratner RE; Christophi CA; Metzger BE; Dabelea D; Bennett PH; Pi-Sunyer X; Fowler S; Kahn SE;
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4774-9. PubMed ID: 18826999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up.
    Aroda VR; Christophi CA; Edelstein SL; Zhang P; Herman WH; Barrett-Connor E; Delahanty LM; Montez MG; Ackermann RT; Zhuo X; Knowler WC; Ratner RE;
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1646-53. PubMed ID: 25706240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial.
    Diabetes Prevention Program Research Group
    Diabetes Care; 2015 Jan; 38(1):51-8. PubMed ID: 25336746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
    ; Knowler WC; Fowler SE; Hamman RF; Christophi CA; Hoffman HJ; Brenneman AT; Brown-Friday JO; Goldberg R; Venditti E; Nathan DM
    Lancet; 2009 Nov; 374(9702):1677-86. PubMed ID: 19878986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study.
    Perreault L; Pan Q; Mather KJ; Watson KE; Hamman RF; Kahn SE;
    Lancet; 2012 Jun; 379(9833):2243-51. PubMed ID: 22683134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study.
    Diabetes Prevention Program Research Group
    Lancet Diabetes Endocrinol; 2015 Nov; 3(11):866-75. PubMed ID: 26377054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial.
    Feig DS; Donovan LE; Zinman B; Sanchez JJ; Asztalos E; Ryan EA; Fantus IG; Hutton E; Armson AB; Lipscombe LL; Simmons D; Barrett JFR; Karanicolas PJ; Tobin S; McIntyre HD; Tian SY; Tomlinson G; Murphy KE;
    Lancet Diabetes Endocrinol; 2020 Oct; 8(10):834-844. PubMed ID: 32946820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study.
    Apolzan JW; Venditti EM; Edelstein SL; Knowler WC; Dabelea D; Boyko EJ; Pi-Sunyer X; Kalyani RR; Franks PW; Srikanthan P; Gadde KM;
    Ann Intern Med; 2019 May; 170(10):682-690. PubMed ID: 31009939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study.
    Goldberg RB; Orchard TJ; Crandall JP; Boyko EJ; Budoff M; Dabelea D; Gadde KM; Knowler WC; Lee CG; Nathan DM; Watson K; Temprosa M;
    Circulation; 2022 May; 145(22):1632-1641. PubMed ID: 35603600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alcohol consumption and diabetes risk in the Diabetes Prevention Program.
    Crandall JP; Polsky S; Howard AA; Perreault L; Bray GA; Barrett-Connor E; Brown-Friday J; Whittington T; Foo S; Ma Y; Edelstein SL;
    Am J Clin Nutr; 2009 Sep; 90(3):595-601. PubMed ID: 19640960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study.
    Aroda VR; Edelstein SL; Goldberg RB; Knowler WC; Marcovina SM; Orchard TJ; Bray GA; Schade DS; Temprosa MG; White NH; Crandall JP;
    J Clin Endocrinol Metab; 2016 Apr; 101(4):1754-61. PubMed ID: 26900641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
    Freemark M; Bursey D
    Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance.
    Florez H; Temprosa MG; Orchard TJ; Mather KJ; Marcovina SM; Barrett-Connor E; Horton E; Saudek C; Pi-Sunyer XF; Ratner RE; Goldberg RB;
    Diabetes Obes Metab; 2014 Apr; 16(4):326-33. PubMed ID: 24118860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term antidiabetic treatment with insulin or metformin has a similar impact on the components of metabolic syndrome in women with gestational diabetes mellitus requiring antidiabetic agents: results of a prospective, randomised study.
    Zawiejska A; Wender-Ozegowska E; Grewling-Szmit K; Brazert M; Brazert J
    J Physiol Pharmacol; 2016 Apr; 67(2):227-33. PubMed ID: 27226182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of metformin for type 2 diabetes prevention: Observational multicenter study from Saudi Arabia.
    Alfayez OM; Alsallum AA; Aljabri AF; Almutairi FS; Al-Azzeh O; Almalki OS; Al Yami MS; Almohammed OA
    Front Public Health; 2022; 10():989072. PubMed ID: 36159298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of metformin poor responders, requiring supplemental insulin, during randomization of metformin versus insulin for the control of gestational diabetes mellitus.
    Ashoush S; El-Said M; Fathi H; Abdelnaby M
    J Obstet Gynaecol Res; 2016 Jun; 42(6):640-7. PubMed ID: 26992090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program.
    Walker EA; Molitch M; Kramer MK; Kahn S; Ma Y; Edelstein S; Smith K; Johnson MK; Kitabchi A; Crandall J
    Diabetes Care; 2006 Sep; 29(9):1997-2002. PubMed ID: 16936143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.